The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions

Launched by UNIVERSITAS PADJADJARAN · Mar 13, 2025

Keywords

ClinConnect Summary

This study is testing whether a topical cream made from ciplukan (Physalis angulata Linn.) extract works to improve psoriasis vulgaris lesions, compared with a standard topical steroid (betametasone valerate 0.1%). Adults will be randomly assigned to use either the ciplukan cream or the steroid cream, twice daily for 14 days. The researchers will look at skin changes using a modified PASI score (MPASI) to rate severity, and they will also measure lesion thickness and inflammation with ultrasound.

To be eligible, people should be 18–60 years old with psoriasis vulgaris and not on systemic psoriasis medicines. They must have stopped systemic therapy or phototherapy for at least about 30 days and stopped other topical psoriasis medicines for at least about 14 days, and have at least 20 psoriasis lesions suitable for treatment. Pregnant or breastfeeding individuals are excluded. The study is taking place in Bandung, Indonesia, and is currently enrolling by invitation; results are not yet available. Participants will receive regular follow-up assessments during the 14-day treatment period.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 - 60 years
• • Diagnosed with psoriasis vulgaris based on medical history, physical examination, and severity assessment using the PASI score
• Exclusion Criteria:
• • Pregnant or breastfeeding women.
• • Patients currently undergoing systemic therapy for psoriasis vulgaris.
• • Patients who have not discontinued systemic therapy/phototherapy for psoriasis vulgaris ≤ 30 days.
• • Patients with psoriasis vulgaris who have not discontinued topical therapy (other than moisturizers) ≤ 14 days.
• • Psoriasis vulgaris lesions located in trauma-prone areas, palms, soles, face, and skin folds.